ClinicalTrials.gg
RecruitingNCT06700395Updated Dec 6, 2024

A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma

A Phase 1 interventional study of TQB2029 injection in Multiple Myeloma, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
78th of 406
136 · median 40
Started
2024
with 46 others
Phase 1
151 of 448
73 open now
Primary completion
2026-03
later than 73 of 274 live
Registered
329th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 78th largest by planned enrollment of the 406 interventional ones that give a count, is one of 47 that started in 2024, is one of 151 in phase 1, reaches primary completion later than 73 of the 274 other live ones, and was the 329th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

This is a study to evaluate the maximum tolerated dose (MTD), dose limiting toxicity (DLT), occurrence of all adverse events (AEs) and serious adverse events (SAEs), pharmacokinetic parameters, pharmacodynamic parameters, immunogenicity, and anti-tumor effects of TQB2029 for injection in Chinese adult subjects with multiple myeloma. The study is divided into Phase Ia and Ib, Phase Ia: dose escalation phase, to evaluate the safety and tolerability of TQB2029 for injection, and determining DLT and MTD; Phase Ib: Dose extension phase, to evaluate the effectiveness of TQB2029 for injection in subjects with multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who voluntarily join the study, sign the form, and have good compliance.
  • Aged from 18 to 75 years; performance status score: 0-2; at least 12 weeks expected survival period.
  • Multiple myeloma with diagnostic records and meeting the International Myeloma Working Group (IMWG) diagnostic criteria
  • There are present
  • The function of main organs is normal.
  • Subjects need to adopt effective methods of .

Exclusion criteria

Exclusion Criteria:

  • Subjects who have taken Chinese patent medicines with anti-tumor indications in the drug instructions that National Medical Products Administration approved within 2 weeks before the first administration.
  • Subjects who received targeted therapy or immunotherapy within 3 weeks before the first medication
  • Subjects who is known allergy to any of the study medications, their analogues, or in the various formulations of any agent.
  • Subjects who has had or currently has other malignant tumors within the past 3 years prior to the first use of medication
  • Subjects who with unrelieved toxic reactions above (CTC AE) grade 1 caused by any previous treatment
  • Subjects who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the expected study treatment period within 4 weeks prior to the first use of medication
  • Subjects who have experienced arterial/venous thrombotic event occurred within 6 months prior to the first administration
  • Subjects with a history of psychotropic drug abuse unable to quit or with mental disorders;
  • Subjects with any severe and/or uncontrolled disease
  • According to the judgment of the investigators, there are accompanying diseases that seriously endanger the safety of patients or affect the completion of the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    TQB2029 injection

    TQB2029 injection, 28 days as a treatment cycle.

    Drug: TQB2029 injection

Interventions

  • DrugTQB2029 injection

    TQB2029 for injection is a bispecific antibody targeting G Protein-Coupled Receptor, Class C, Group 5, Member D (GPRC5D) and Cluster of Differentiation 3 (CD3) . By recruiting and activating CD3 positive T cells, it induces T cells to kill malignant plasma cells expressing GPRC5D, thereby inhibiting the occurrence and development of tumors.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT)

    DLT refers to any of the following events in the first administration of TQB2029 for injection to the end of the first treatment cycle (C1D28) that the investigator and the sponsor consider to be related to the treatment of TQB2029 for injection.

    Time frame: During the first 28 days

  2. Maximum tolerated dose (MTD)

    After the experiment is completed, sequential regression is used to determine the maximum tolerated dose (MTD). Specifically, calculate the toxicity rate of each dose group and select the dose closest to the target toxicity rate as MTD.

    Time frame: Up to 18 months

  3. Recommended Phase II Dose (RP2D)

    Determine RP2D based on target toxicity rates for each dose group

    Time frame: Up to 18 months

  4. Number of patients with adverse events (AEs) and serious adverse events (SAEs)

    Assessed by the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTCAE) v5.0.

    Time frame: Up to 18 months

Secondary outcomes

  1. Elimination half-life (to be used in one-or non- compartmental model) (t1/2)

    t1/2 is time it takes for the blood concentration of TQB2029 or metabolite(s) to drop by half.

    Time frame: The first and second treatment cycle: 0 hours, 2 hours, 6 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 168 hours after dosing on the first day, 0 hours on the 15th day, and 0 hours on the 22nd day.

  2. Maximum (peak) plasma drug concentration (Cmax)

    Cmax is the maximum plasma concentration of TQB2029 or metabolite(s).

    Time frame: The first and second treatment cycle: 0 hours, 2 hours, 6 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 168 hours after dosing on the first day, 0 hours on the 15th day, and 0 hours on the 22nd day.

  3. Area under the plasma concentration-time curve from time zero to time t (AUC0-t)

    To characterize the pharmacokinetics of TQB2029 by assessment of area under the plasma concentration time curve from the first dose to infinity.

    Time frame: The first and second treatment cycle: 0 hours, 2 hours, 6 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 168 hours after dosing on the first day, 0 hours on the 15th day, and 0 hours on the 22nd day.

  4. Apparent clearance rate (CL/F)

    The apparent clearance rate is used to predict dynamic distribution rates and evaluate the dynamics of nutrients.

    Time frame: The first and second treatment cycle: 0 hours, 2 hours, 6 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 168 hours after dosing on the first day, 0 hours on the 15th day, and 0 hours on the 22nd day.

  5. Volume of distribution(Vz/F)

    Refers to the volume of bodily fluids required for drugs to be distributed in the body according to the plasma drug concentration at the time when the drug reaches dynamic equilibrium in the body.

    Time frame: The first and second treatment cycle: 0 hours, 2 hours, 6 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 168 hours after dosing on the first day, 0 hours on the 15th day, and 0 hours on the 22nd day.

  6. Blood drug trough concentration (Cmin)

    Describe the minimum value of drug concentration.

    Time frame: The first and second treatment cycle: 0 hours, 2 hours, 6 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 168 hours after dosing on the first day, 0 hours on the 15th day, and 0 hours on the 22nd day.

  7. Exploring the correlation between changes in cytokine levels, lymphocyte subpopulation levels, and therapeutic efficacy

    Pharmacodynamic indicators:The levels of peripheral blood serum cytokines (IL-2, IL-6, IL-8, IL-10, Interferon gamma (IFN - γ), tumor necrosis factor-α (TNF - α), interleukin 2 receptor alpha (IL-2R α), interleukin 2 receptor beta (IL-2R β), IL-2R γ, lymphocyte subsets, T cell activation markers (percentage of Cluster of (Differentiation) 25+T cells, percentage of Ki67+T cells), and the expression levels of Programmed cell death 1 (PD-1), T-cell immunoglobulin and mucin domain 3 (TIM-3), Lymphocyte-activation gene 3 (LAG-3), cytotoxic T-lymphocyte associated protein 4 (CTLA-4) on the surface of T cells.

    Time frame: The first and second treatment cycle: 0, 2, 6, 24, 48, 72 hours after dosing on the first day, 0 hours on the 15th day;The first treatment cycle: 0 hours on the 8th day;0 hours on the 22th day;The third and fourth treatment cycle: 0 hours on the 1st day.

  8. Immunogenicity analysis- positive anti drug antibodies (ADA)

    Describe the number, proportion, and 95% confidence interval of positive anti drug antibodies (ADA) after medication, as well as the time and titer of ADA production

    Time frame: The first, third, sixth, twelfth treatment cycle: 0 hours on the first day;and End of Treatment Visit (EOT)

  9. Overall response rate (ORR)

    Proportion of subjects with best response as PR, VGPR, CR, sCR.

    Time frame: Up to 18 months

  10. Very good partial response rate (VGPR)

    Proportion of subjects whose best response is VGPR, CR, sCR

    Time frame: Up to 18 months

  11. Complete Response (CR)

    Proportion of subjects whose best response is CR.

    Time frame: Up to 18 months

  12. Strict Complete Response (sCR) Rate

    Proportion of subjects whose best response is sCR.

    Time frame: Up to 18 months

  13. Negative rate of minimal residual disease (MRD)

    The proportion of subjects with negative MRD (\<10-5, multicolor flow cytometry or next-generation sequencing) at any time point from the first administration of the trial drug to disease progression or before receiving new anti-tumor therapy.

    Time frame: Up to 18 months

  14. Duration of remission (DOR)

    For all subjects whose best response was PR, VGPR, CR, sCR, the time from the date of first achieving PR, VGPR, CR, sCR to the date of first definite disease progression or (any cause) death(whichever occurs first).

    Time frame: Up to 18 months

  15. Time to first remission (TTR)

    Among all the subjects whose best response is PR, VGPR, CR, sCR, the time from the first administration of the test drug to the date of the first PR and above remission.

    Time frame: Up to 18 months

  16. Progression-free survival (PFS)

    The time between the first dose of the trial drug and the date of first definite disease progression or death (from any cause), whichever occurs first.

    Time frame: Up to 18 months

  17. Overall survival (OS)

    Time from first dose of study drug to date of death from any cause.

    Time frame: Up to 18 months

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2026, 16 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 16 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Nov 22, 2024
StartActual
Nov 28, 2024
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2028
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06700395
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Nov 28, 2024
Primary completion
Mar 2026 (estimated)
Completion
Mar 2028 (estimated)
Last update
Dec 6, 2024

Study contacts

Ting Niu, Doctor
Contact
tingniu@sina.com
028-85423046
Peng Liu, Doctor
Contact
Liu.peng@zs-hospital.sh.cn
021-60267405

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion